Magenta Therapeutics, Inc.MGTANASDAQ
Loading
Year-over-year research & development expense growth
Latest
84.35%
↓ 53% vs avg
Percentile
P91
Near historical high
Streak
3 qtr
Consecutive growthRecovering
Average
180.40%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 84.35% |
| Q3 2025 | 23.76% |
| Q2 2025 | -2.78% |
| Q1 2025 | -59.70% |
| Q4 2024 | 162.34% |
| Q3 2024 | 41.36% |
| Q2 2024 | 0.00% |
| Q3 2023 | 5626.62% |
| Q2 2023 | -98.26% |
| Q1 2023 | -49.37% |
| Q4 2022 | 40.97% |
| Q3 2022 | -3.46% |
| Q2 2022 | -29.88% |
| Q1 2022 | 26.18% |
| Q4 2021 | 21.48% |
| Q3 2021 | -3.00% |
| Q2 2021 | -5.11% |
| Q1 2021 | -4.31% |
| Q4 2020 | 3.99% |
| Q3 2020 | -6.53% |
| Q2 2020 | -9.69% |
| Q1 2020 | -25.39% |
| Q4 2019 | 13.25% |
| Q3 2019 | 23.01% |
| Q2 2019 | 27.48% |
| Q1 2019 | -14.96% |
| Q4 2018 | 8.51% |
| Q3 2018 | 17.92% |
| Q2 2018 | 23.37% |
| Q1 2018 | 41.40% |
| Q4 2017 | 6.55% |
| Q3 2017 | -62.29% |
| Q2 2017 | 315.89% |
| Q1 2017 | 0.00% |